Rohit Nathani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rohit Nathani has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Cathy Nguyen
University of Texas Southwestern Medical Center, Dallas (R.N., C.N., Q.L., N.M.-Y., S.T., J.A.B., S.G.).
3 shared publicationsQiang Li
University of Texas Southwestern Medical Center, Dallas (R.N., C.N., Q.L., N.M.-Y., S.T., J.A.B., S.G.).
3 shared publications- Saket Girotra
University of Texas Southwestern Medical Center, Dallas (S.G.).
3 shared publications - Brian C. Lund
Center for Access & Delivery Research and Evaluation, Iowa City Veterans Affairs Health Care System, Iowa City, IA, USA
2 shared publications - Joshua A. Beckman
Division of Vascular Medicine, University of Texas Southwestern Medical Center, Dallas (J.A.B.).
2 shared publications - Kim G. Smolderen
Yale School of Medicine
2 shared publications
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (10)
Statins Use in Veterans With Peripheral Artery Disease: Insights From the PEARLS Study
BACKGROUND: Guidelines recommend high-intensity statins in patients with peripheral artery disease (PAD). We examined contemporary use of statins among real-world patients with a new diagnosis of PAD. METHODS: Within a national registry of Veterans with incident PAD, we used pharmacy claims data to determine active statin use within 1 year of PAD diagnosis. We also used laboratory data to evaluate lipid levels. Hierarchical multivariable logistic regression was used to identify variables associated with the use of any statin and high-intensity statin 1 year after PAD diagnosis and quantify variation in statin use across sites. RESULTS: Among 91 970 patients with PAD alive at 1 year, the median age was 70 years, 97.2% were men, and 18.6% were Black. At 1 year, 64 231 (69.9%) patients were on a statin, and 34 017 (37.0%) were on a high-intensity statin. Among nonstatin users, 53.4% (14 834/27 739) had not been prescribed a statin at any time in the preceding 3 years. Overall, the median low-density lipoprotein cholesterol was 81.6 mg/dL and was lower in those on high-intensity statins versus low/moderate-intensity statins versus no statins (72.2 versus 78.0 versus 100 mg/dL). Age, prior history of coronary artery disease, cerebrovascular disease, hypertension, diabetes, and current or former smoking history, obesity, and revascularization during the initial 6 months were associated with higher statin and high-intensity statin use (among statin users). At the site level, there was modest variation in statin use, especially high-intensity statins, which ranged from 20% to 54% with an overall median odds ratio of 1.39 (95% CI, 1.32–1.46). CONCLUSIONS: Nearly 70% of patients with PAD were receiving a statin within 1 year of PAD diagnosis. However, use of high-intensity statins and nonstatin lipid-lowering therapy remained suboptimal. Moreover, there was modest variation in use of statins, especially high-intensity statins, across sites, highlighting opportunities for improving guideline-concordant care in patients with PAD.
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (10)
Statins Use in Veterans With Peripheral Artery Disease: Insights From the PEARLS Study
BACKGROUND: Guidelines recommend high-intensity statins in patients with peripheral artery disease (PAD). We examined contemporary use of statins among real-world patients with a new diagnosis of PAD. METHODS: Within a national registry of Veterans with incident PAD, we used pharmacy claims data to determine active statin use within 1 year of PAD diagnosis. We also used laboratory data to evaluate lipid levels. Hierarchical multivariable logistic regression was used to identify variables associated with the use of any statin and high-intensity statin 1 year after PAD diagnosis and quantify variation in statin use across sites. RESULTS: Among 91 970 patients with PAD alive at 1 year, the median age was 70 years, 97.2% were men, and 18.6% were Black. At 1 year, 64 231 (69.9%) patients were on a statin, and 34 017 (37.0%) were on a high-intensity statin. Among nonstatin users, 53.4% (14 834/27 739) had not been prescribed a statin at any time in the preceding 3 years. Overall, the median low-density lipoprotein cholesterol was 81.6 mg/dL and was lower in those on high-intensity statins versus low/moderate-intensity statins versus no statins (72.2 versus 78.0 versus 100 mg/dL). Age, prior history of coronary artery disease, cerebrovascular disease, hypertension, diabetes, and current or former smoking history, obesity, and revascularization during the initial 6 months were associated with higher statin and high-intensity statin use (among statin users). At the site level, there was modest variation in statin use, especially high-intensity statins, which ranged from 20% to 54% with an overall median odds ratio of 1.39 (95% CI, 1.32–1.46). CONCLUSIONS: Nearly 70% of patients with PAD were receiving a statin within 1 year of PAD diagnosis. However, use of high-intensity statins and nonstatin lipid-lowering therapy remained suboptimal. Moreover, there was modest variation in use of statins, especially high-intensity statins, across sites, highlighting opportunities for improving guideline-concordant care in patients with PAD.
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (7) , e038403
Long‐Term Outcomes of Peripheral Artery Disease in Veterans: Analysis of the Peripheral Artery Disease Long‐Term Survival Study (PEARLS)
Background: Contemporary research in peripheral artery disease (PAD) remains limited due to lack of a national registry and low accuracy of diagnosis codes to identify patients with PAD. Methods: Leveraging a novel natural language processing system that identifies PAD with high accuracy using ankle‐brachial index and toe‐brachial index values, we created a registry of 103 748 patients with new‐onset PAD in the Veterans Health Administration. Study end points include mortality, cardiovascular events (hospitalization for acute myocardial infarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using Veterans Affairs and non–Veterans Affairs encounters. Results: The mean age was 70.6 years; 97.3% were male, and 18.5% self‐identified as Black. The mean ankle‐brachial index value was 0.78 (SD: 0.26) and the mean toe‐brachial index value was 0.51 (SD: 0.19). A majority of patients were current (27.1%) or former (30.0%) smokers. Prevalence of hypertension (86.6%), heart failure (22.7%), diabetes (54.8%), chronic kidney disease (23.6%), and chronic obstructive pulmonary disease (35.4%) was high. At 1 year, 9.4% of patients had died. The 1‐year incidence of cardiovascular events was 5.6 per 100 patient‐years and limb events was 7.0 per 100 patient‐years. Conclusions: We have successfully launched a registry of >100 000 patients with a new diagnosis of PAD in the Veterans Health Administration, the largest integrated health system in the United States. The incidence of death and clinical events in our cohort is high. Ongoing studies will yield important insights regarding improving care and outcomes in this high‐risk group.
- 1 April 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (7) , e038403
Open AccessLong‐Term Outcomes of Peripheral Artery Disease in Veterans: Analysis of the Peripheral Artery Disease Long‐Term Survival Study (PEARLS)
Background: Contemporary research in peripheral artery disease (PAD) remains limited due to lack of a national registry and low accuracy of diagnosis codes to identify patients with PAD. Methods: Leveraging a novel natural language processing system that identifies PAD with high accuracy using ankle‐brachial index and toe‐brachial index values, we created a registry of 103 748 patients with new‐onset PAD in the Veterans Health Administration. Study end points include mortality, cardiovascular events (hospitalization for acute myocardial infarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using Veterans Affairs and non–Veterans Affairs encounters. Results: The mean age was 70.6 years; 97.3% were male, and 18.5% self‐identified as Black. The mean ankle‐brachial index value was 0.78 (SD: 0.26) and the mean toe‐brachial index value was 0.51 (SD: 0.19). A majority of patients were current (27.1%) or former (30.0%) smokers. Prevalence of hypertension (86.6%), heart failure (22.7%), diabetes (54.8%), chronic kidney disease (23.6%), and chronic obstructive pulmonary disease (35.4%) was high. At 1 year, 9.4% of patients had died. The 1‐year incidence of cardiovascular events was 5.6 per 100 patient‐years and limb events was 7.0 per 100 patient‐years. Conclusions: We have successfully launched a registry of >100 000 patients with a new diagnosis of PAD in the Veterans Health Administration, the largest integrated health system in the United States. The incidence of death and clinical events in our cohort is high. Ongoing studies will yield important insights regarding improving care and outcomes in this high‐risk group.